NASDAQ: ALGS Investor Notice: Investigation Over Potential Wrongdoing at Aligos Therapeutics, Inc.

An investigation on behalf of investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential wrongdoing at Aligos Therapeutics, Inc. was announced.

San Diego, CA — (SBWIRE) — 04/15/2022 — Certain directors of Aligos Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm concerns whether certain Aligos Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Francisco, CA based Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
On or around October 15, 2020, Aligos Therapeutics, Inc conducted its initial public offering (“IPO”), offering 10 million shares of common stock priced at $15.00 per share.
On January 6, 2022, Aligos Therapeutics, Inc issued a press release stating “announc[ing] that it has halted further development of its STOPSβ„’ drug candidate, ALG-010133, in development to address chronic hepatitis B (CHB).” Aligos stated that “[t]his decision is based on emerging data from the Phase 1 Study ALG-010133-101 that indicate that at the projected efficacious dose (400 mg, estimated to achieve liver exposures >3 x EC90 for HBsAg inhibition) there is no meaningful HBsAg reduction. Furthermore, higher doses levels (maximum feasible dose is 600 mg) that were planned to be evaluated in a subsequent cohort are very unlikely to reach the 1 log10 IU/mL HBsAg reduction level that Aligos had previously defined as necessary to advance the program.” Accordingly, “[b]ased on this information, Aligos management reviewed the data with members of the study’s Study Review Committee (SRC) and jointly concluded that these data were not sufficient to support further development of ALG-010133 and that dosing should be discontinued.”

Shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) declined to as low as $3.08 per share during January 19, 2022.

Those who purchased shares of Aligos Therapeutics, Inc. (NASDAQ: ALGS) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit: http://www.sbwire.com/press-releases/nasdaq-algs-investor-notice-investigation-over-potential-wrongdoing-at-aligos-therapeutics-inc-1356147.htm

Media Relations Contact

Christopher Clausen
Shareholders Foundation
Telephone: +1-(858)-779-1554
Email: Click to Email Christopher Clausen
Web: http://www.ShareholdersFoundation.com